Hifibio Therapeutics Closes $75 Million Series D Financing To Accelerate Pipeline With Two Lead Immuno-Oncology Programs And Validate Its Dis™ Approach In The Clinic
Jun 14, 2021•about 4 years ago
Amount Raised
$75 Million
Round Type
series d
Description
HiFiBiO Therapeutics, a multinational biotechnology company with unique expertise in immune modulation and drug intelligent science, today announced the completion of an oversubscribed $75M Series D financing round. The funding was led by the new investor Mirae Asset Financial Group. Further, B Capital Group, Sherpa, Maison Capital, Trinity Innovation Fund, Grand Mount, and HKSTP Venture Fund also participated in this round. The existing shareholders IDG, Sequoia, Legend Star, and Hengxu continued to invest.
Funding Insights
Based on industry dataTech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech